Erasca shares slide after early ERAS-0015 Phase 1 results
Erasca Inc. (NASDAQ:ERAS) stock dropped 5% in after-hours trading Monday after the company released preliminary Phase 1 dose escalation data for ERAS-0015, a pan-RAS molecular glue. Early results from U.S. and China Phase 1 trials show notable unconfirmed overall response rates in KRAS G12X non-small cell lung cancer and pancreatic cancer at specif…